TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|
Turnover | 48.32%2.04B | 50.97%3.05B | 51.45%1.38B | 25.41%2.02B | 18.55%908.79M | 45.95%1.61B | --766.56M | 31.96%1.1B | --836.63M |
Operating income | 48.32%2.04B | 50.97%3.05B | 51.45%1.38B | 25.41%2.02B | 18.55%908.79M | 45.95%1.61B | 766.56M | 31.96%1.1B | 836.63M |
Cost of sales | -46.62%-557.81M | -52.22%-836.8M | -53.91%-380.45M | -29.17%-549.72M | -21.43%-247.19M | -37.06%-425.58M | ---203.57M | -36.15%-310.51M | ---228.07M |
Operating expenses | -46.62%-557.81M | -52.22%-836.8M | -53.91%-380.45M | -29.17%-549.72M | -21.43%-247.19M | -37.06%-425.58M | -203.57M | -36.15%-310.51M | -228.07M |
Gross profit | 48.97%1.48B | 50.50%2.21B | 50.53%995.92M | 24.06%1.47B | 17.52%661.6M | 49.42%1.19B | 562.99M | 30.40%793.55M | 608.56M |
Selling expenses | -34.83%-109.32M | -36.30%-159.21M | -50.50%-81.08M | 4.15%-116.81M | 9.65%-53.87M | -41.25%-121.86M | ---59.63M | -40.20%-86.27M | ---61.54M |
Employee expense | -30.44%-711.91M | -50.14%-1.18B | -61.99%-545.77M | -11.60%-785.04M | 1.66%-336.91M | -49.92%-703.46M | ---342.59M | -39.70%-469.22M | ---335.87M |
Depreciation and amortization | -31.55%-271.22M | -24.63%-447.18M | -20.47%-206.17M | -18.13%-358.8M | -18.62%-171.13M | -23.69%-303.74M | ---144.28M | -27.59%-245.57M | ---192.46M |
Revaluation surplus | ---- | 6,522.55%119.33M | 11,159.41%119.33M | 99.08%-1.86M | 98.71%-1.08M | -1,344.77%-201.3M | ---83.38M | ---13.93M | ---- |
-Changes in the fair value of other assets | ---- | 6,522.55%119.33M | 11,159.41%119.33M | 99.08%-1.86M | 98.71%-1.08M | -1,344.77%-201.3M | ---83.38M | ---13.93M | ---- |
Special items of operating profit | -43.39%-322.41M | -48.36%-491.26M | -65.18%-224.85M | -34.69%-331.12M | -28.07%-136.12M | -33.40%-245.84M | ---106.29M | -23.49%-184.29M | ---149.23M |
Operating profit | 19.86%68.79M | 146.44%56.92M | 252.97%57.39M | 68.61%-122.56M | 78.33%-37.52M | -89.78%-390.45M | -173.17M | -57.61%-205.74M | -130.53M |
Financing cost | 4.78%-27.9M | 30.23%-54.65M | 39.24%-29.3M | 10.66%-78.32M | -17.77%-48.22M | -41.54%-87.67M | ---40.94M | -21.41%-61.94M | ---51.02M |
Earning before tax | 45.55%40.89M | 101.13%2.28M | 132.77%28.1M | 57.98%-200.88M | 59.96%-85.74M | -78.62%-478.12M | -214.12M | -47.44%-267.68M | -181.55M |
Tax | -55.01%-29.99M | -32.78%-28.88M | -98.65%-19.35M | -408.10%-21.75M | -209.51%-9.74M | 210.76%7.06M | --8.89M | ---6.37M | ---- |
After-tax profit from continuing operations | 24.64%10.91M | 88.05%-26.6M | 109.17%8.75M | 52.74%-222.63M | 53.48%-95.48M | -71.89%-471.06M | -205.22M | -50.95%-274.05M | -181.55M |
Earning after tax | 24.64%10.91M | 88.05%-26.6M | 109.17%8.75M | 52.74%-222.63M | 53.48%-95.48M | -71.89%-471.06M | -205.22M | -50.95%-274.05M | -181.55M |
Profit attributable to shareholders | 24.64%10.91M | 88.05%-26.6M | 109.17%8.75M | 52.74%-222.63M | 53.48%-95.48M | -71.89%-471.06M | -205.22M | -50.95%-274.05M | -181.55M |
Basic earnings per share | 0.00%0.08 | 90.60%-0.22 | 108.00%0.08 | 56.83%-2.34 | 57.98%-1 | -68.85%-5.42 | -2.38 | -50.00%-3.21 | -2.14 |
Diluted earnings per share | 14.29%0.08 | 90.60%-0.22 | 107.00%0.07 | 56.83%-2.34 | 57.98%-1 | -68.85%-5.42 | -2.38 | -50.00%-3.21 | -2.14 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion |
Auditor | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.